Skip to search boxSkip to navigationSkip to main content

A novel splice variant of HYAL-4 drives malignant transformation and predicts outcome in patients with bladder cancer

  • Vinata B. Lokeshwar(corresponding author)
    ,
  • Daley S. Morera
    ,
  • Sarrah L. Hasanali
    ,
  • Travis J. Yates
    ,
  • Marie C. Hupe
    ,
  • Judith Knapp
*Corresponding author for this work
Scholary Output:
Contribution to journal
Article
Research
Peer-review

Open access

Sustainable Development Goals

  • SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well

Abstract

Purpose: Poor prognosis of patients with muscle-invasive bladder cancer that often metastasizes drives the need for discovery of molecular determinants of bladder cancer progression. Chondroitin sulfate proteoglycans, including CD44, regulate cancer progression; however, the identity of a chondroitinase (Chase) that cleaves chondroitin sulfate from proteoglycans is unknown. HYAL-4 is an understudied gene suspected to encode a Chase, with no known biological function. We evaluated HYAL-4 expression and its role in bladder cancer. Experimental Design: In clinical specimens, HYAL-4 wild-type (Wt) and V1 expression was evaluated by RT-qPCR, IHC, and/or immunoblotting; a novel assay measured Chase activity. Wt and V1 were stably expressed or silenced in normal urothelial and three bladder cancer cell lines. Transfectants were analyzed for stem cell phenotype, invasive signature and tumorigenesis, and metastasis in four xenograft models, including orthotopic bladder. Results: HYAL-4 expression, specifically a novel splice variant (V1), was elevated in bladder tumors; Wt expression was barely detectable. V1 encoded a truncated 349 amino acid protein that was secreted. In bladder cancer tissues, V1 levels associated with metastasis and cancer-specific survival with high efficacy and encoded Chase activity. V1 cleaved chondroitin-6-sulfate from CD44, increasing CD44 secretion. V1 induced stem cell phenotype, motility/invasion, and an invasive signature. CD44 knockdown abrogated these phenotypes. V1-expressing urothelial cells developed angiogenic, muscle-invasive tumors. V1-expressing bladder cancer cells formed tumors at low density and formed metastatic bladder tumors when implanted orthotopically. Conclusions: Our study discovered the first naturally-occurring eukaryotic/human Chase and connected it to disease pathology, specifically cancer. V1-Chase is a driver of malignant bladder cancer and potential predictor of outcome in patients with bladder cancer.

Publication Information

Output type

Scholary Output:
Contribution to journal
Article
Research
Peer-review

Original language

English (US)

Pages from-to (Number of pages)

Pages 3455-3467 (13 pages)

Journal (Volume, Issue Number)

Clinical Cancer Research (Volume 26, Issue 13)

Publication milestones

  • Published - 07/2020

Publication status

Published - 07/2020

ISSN

1078-0432

Publication IDs

  • Scopus: 85087469685
  • PubMed: 32094233

Publication metrics

Metrics

SciVal
Author count
22
SciVal
Paper percentile
50
Scopus
citations
Fractional count
5
Fractional count
0.23
Fractional count
17
Fractional count
0.77
Fractional count
5
Fractional count
1

PlumX, opens in new tab

Captures
10
Citation count
17

Funding Details

This study is dedicated to the memory of Ms. Neetika Dhir who, together with Dr. Vinata Lokeshwar, first cloned HYAL-4 V1. Ms. Dhir passed away too soon on December 22, 2008. The research reported in this publication was partly supported by the NCI of the NIH, under the awards 1R01CA227277-01A1 (to V.B. Lokeshwar), 1F31 CA236437-01 (to D.S. Morera), and 1F31CA210612-01 to A.R. Jordan) and from the United States Army Medical Research and Development Command (USAMRDC) of the Department of Defense, under award number W81XWH-18-1-0277 (to V.B. Lokeshwar). The content of this article is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.
FundersFunding numbers
USAMRDC
-
NCI
-
NIH
1F31 CA236437-01, 1F31CA210612-01, 1R01CA227277-01A1
DOD
W81XWH-18-1-0277